Trinity Biotech (TRIB) Current Assets (2009 - 2025)

Trinity Biotech (TRIB) has reported Current Assets for 17 consecutive years, with $35.9 million the latest figure, recorded in Q4 2025.

• Quarterly Current Assets fell 12.7% year-over-year to $35.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $35.9 million (down 12.7% YoY) and the FY2025 annual result came in at $35.9 million, down 12.7% from the prior year.
• Current Assets grew to $35.9 million in Q4 2025 per TRIB's latest filing, from $33.0 million in the prior quarter.
• Over the last five years, Current Assets for TRIB reached as high as $87.6 million in Q1 2021 and fell as low as $33.0 million in Q2 2025.
• A 5-year average of $54.1 million and a median of $48.3 million in 2022 frame the typical range for Current Assets.
• Annual changes were most pronounced in 2021 — Current Assets advanced 29.85% — and 2022, when it slumped 36.31%.
• Year by year, Current Assets stood at $72.7 million in 2021, then plunged by 35.8% to $46.7 million in 2022, then dropped by 16.34% to $39.0 million in 2023, then climbed by 5.34% to $41.1 million in 2024, then declined by 12.7% to $35.9 million in 2025.
• According to Business Quant data, Current Assets over the past three periods registered $35.9 million, $33.0 million, and $41.1 million for Q4 2025, Q2 2025, and Q4 2024 respectively.